Evommune, Inc. is a clinical-stage biotechnology company. It engages in the development of medicines for inflammatory diseases. The company was founded by Luis C. Pena, Eugene Andrew Bauer, and Hans Hofland in 2020 and is headquartered in Palo Alto, CA.
Sector:
Health Technology
Industry:
Pharmaceuticals Major
Employees:
48
Frequently Asked Questions
What is Market Cap of Evommune Inc.?
Market cap, also known as market capitalization, is the total market value of a company. It's calculated by multiplying the current market price by the total number of shares outstanding. Evommune Inc. market cap is $745.22M.
What is the 52-week high for Evommune Inc.?
52 week high is the highest price of a stock in the past 52 weeks, or one year. Evommune Inc. 52 week high is $33.20 as of June 06, 2026.
What is the 52-week low for Evommune Inc.?
52 week low is the lowest price of a stock in the past 52 weeks, or one year. Evommune Inc. 52 week low is $13.89 as of June 06, 2026.
What is Evommune Inc. stock price today?
Evommune Inc. stock price today is $19.92.
What was Evommune Inc. stock price yesterday?
Evommune Inc. stock price yesterday was $20.69.
What is the PE ratio of Evommune Inc.?
The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company. It's calculated by dividing the current share price by the earnings per share (or EPS). It can also be calculated by dividing the company's Market Cap by the Net Profit. Evommune Inc.'s P/E ratio is -8.34.
What is the Price-to-Book ratio of Evommune Inc.?
The Price-to-Book (P/B) ratio is a commonly used tool for valuing a company. It's calculated by dividing a company's market capitalization by its book value. Evommune Inc. P/B ratio is 2.3558.
What is the 50-day moving average of Evommune Inc.?
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It's calculated by averaging the closing stock price over the previous 50 trading days. Evommune Inc. 50-day moving average is $23.97.
